Apellis Pharmaceuticals (APLS) Projected to Post Earnings on Wednesday

Apellis Pharmaceuticals (NASDAQ:APLS) is expected to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.38) per share and revenue of $203.5830 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.86. The firm had revenue of $199.91 million for the quarter, compared to analyst estimates of $199.28 million. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The company’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) earnings per share. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Apellis Pharmaceuticals Stock Performance

APLS stock opened at $40.96 on Monday. The business’s 50-day moving average price is $29.22 and its two-hundred day moving average price is $25.24. The company has a current ratio of 3.14, a quick ratio of 2.70 and a debt-to-equity ratio of 0.98. The firm has a market cap of $5.24 billion, a PE ratio of 315.10 and a beta of -0.24. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $41.00.

Wall Street Analyst Weigh In

Several research firms have issued reports on APLS. Wells Fargo & Company downgraded Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $26.00 to $41.00 in a research note on Friday, April 17th. HC Wainwright downgraded Apellis Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the company from $48.00 to $41.00 in a research note on Wednesday, April 1st. Jefferies Financial Group downgraded Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Barclays lifted their price target on Apellis Pharmaceuticals from $24.00 to $41.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 1st. Finally, Robert W. Baird downgraded Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Three equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $34.89.

Institutional Trading of Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of APLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Apellis Pharmaceuticals by 207.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock valued at $667,000 after acquiring an additional 19,944 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Apellis Pharmaceuticals by 26.6% in the first quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after acquiring an additional 64,742 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Apellis Pharmaceuticals by 4.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock valued at $4,869,000 after acquiring an additional 9,747 shares during the last quarter. Focus Partners Wealth increased its position in shares of Apellis Pharmaceuticals by 118.4% in the first quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock valued at $479,000 after acquiring an additional 11,862 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Apellis Pharmaceuticals by 1,146.2% in the first quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock valued at $522,000 after acquiring an additional 22,052 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.